Underdiagnosis still a problem despite improved assessment tools ...

Tardive dyskinesia, or TD, is a drug-induced movement disorder that can occur in individuals taking certain medications that block dopamine receptors in the brain. Most commonly, cases of TD are ...

Tardive dyskinesia (TD) and related drug-induced movement disorders represent a spectrum of involuntary hyperkinetic and hypokinetic syndromes arising predominantly from long-term exposure to dopamine ...

Differentiating tardive dyskinesia from other movement disorders can be challenging. "One major criterion is the history of exposure to neuroleptic medications," said Jeff Bronstein, MD, PhD, of the ...

This is a preview. Log in through your library . Abstract Purpose Tardive dyskinesia (TD) is a common but serious hyperkinetic movement disorder and side effect of antipsychotic medications used to ...

TEL AVIV, Israel, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that a new analysis from the European cohort of the RIM-TD open-label ...

Neurocrine Biosciences, maker of the first drug approved by the FDA to treat tardive dyskinesia, continues to throw its weight behind efforts to improve screening, monitoring and general awareness of ...

New analysis from the IMPACT-TD Registry demonstrates that treatment with AUSTEDO and AUSTEDO XR led to reductions in Abnormal Involuntary ...

SAN DIEGO, Aug. 29, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today presented findings from a data analysis of KINECT ®-4 demonstrating a comparable pattern of ...

Please provide your email address to receive an email when new articles are posted on . Neurocrine Biosciences Inc. recently presented data on comorbidities, polypharmacy and treatment patterns of ...